Ketazocine

From Self-sufficiency
Revision as of 11:59, 25 April 2010 by Meodipt (Talk)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Ketazocine
File:Ketazocine.svg
Systematic (IUPAC) name
(2S,6R,11R)-3-(cyclopropylmethyl)-8-hydroxy-6,11-dimethyl-3,4,5,6-tetrahydro-2,6-methano-3-benzazocin-1(2H)-one
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  •  ?
Identifiers
CAS Number 36292-69-0
ATC code none
PubChem CID 3054741
ChemSpider 2316328
Chemical data
Formula C18H23NO2
Molar mass 285.38 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Ketazocine (INN), also known as ketocyclazocine, is a benzomorphan derivative used in opioid receptor research. Ketocyclazocine is an exogenous opioid that binds to the kappa opioid receptor.

Activation of this receptor causes a decrease in pain sensations and increased sleepiness but can also cause psychological symptoms such as feelings of unease, paranoia, and hallucinations. It also causes an increase in urine production because it inhibits the release of vasopressin. (Vasopressin is an endogenous substance that assists in regulating fluid and electrolyte balance in the body and decreases the amount of water released into the urine.)

Unlike other opioids, substances that only bind to the kappa receptor theoretically do not impair the normal drive to breathe.

See also

References